Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10616
Peer-review started: May 7, 2021
First decision: July 26, 2021
Revised: August 12, 2021
Accepted: October 25, 2021
Article in press: October 25, 2021
Published online: December 6, 2021
Processing time: 207 Days and 0.4 Hours
Abnormal bone metabolism and renal anemia seriously affect the prognosis of patients with chronic kidney disease (CKD). Currently, there are few studies on the evaluation of their mutual connection. With the availability of hypoxia-inducible factor (HIF) stabilizers, more therapeutic choices for renal anemia are expected in the future. However, the effects posed by the hypoxic environment on abnormal bone metabolism remain incompletely understood. If we can find evidence that HIF could improve both complications, it will be a great advantage to improve the prognosis of patients with CKD.
The purpose of this article is to summarize the relationship between renal anemia and abnormal bone metabolism, and to discuss the influence of hypoxia on bone meta
To clarify the bidirectional relationship between anemia and abnormal bone meta
We searched relevant articles published in multiple languages and fields, summarized important information, and drew our conclusions.
Anemia and bone metabolism interact. The hypoxic environment could affect osteoblast/osteoclast maturation and differentiation, enhance the paracrine effect of mesenchymal stem cells, and reduce the inhibitory effect of fibroblast growth factor 23 on osteocyte differentiation. Hypoxia potentially improves bone metabolism, but the optimal concentration and duration of hypoxia remain unclear and need further study.
There is a bidirectional relationship between renal anemia and abnormal bone metabolism. The relationship has rarely been studied. Hypoxia may improve bone metabolism, but the concentration and duration of hypoxia remain unclear and need further study. To improve the quality of life of patients with CKD, future studies should address the effect of HIF on bone metabolism while treating anemia, and HIF may be a useful treatment for improving the prognosis of patients with CKD.
In future studies, we can focus more on the exact degree of hypoxia concentration and duration required for improving bone metabolism.